Xconomy: GSK Backs SpringLeaf, Prexa Nabs $7M from Advent & Shire, Acetylon Gets $5M Partnership, & More Boston-Area Life Sciences News
Summary
GSK Backs SpringLeaf, Prexa Nabs $7M from Advent & Shire, Acetylon Gets $5M Partnership, & More Boston-Area Life Sciences News Xconomy Boston — New England biotechs made headlines this week with partnerships and financing news.—Cambridge, MA-based Seventh Sense Biosystems announced it had raised $4.5 million in an extension of its Series A financing round, to put toward developing its system for collecting blood in a safer and less painless manner.—Acetylon Pharmaceuticals of Boston announced it could get as much as $4.85 million through a partnership with the Leukemia & Lymphoma Society surrounding its experimental drug for multiple myeloma.The team, Zinaura Pharmaceuticals, didn’t win the big check, but it’s developing its drug candidate to target new seizure pathways without causing toxicity, addiction, sedation, or cognitive impairment.—SpringLeaf Therapeutics scored $15 million in a Series B financing led by SR One, the corporate VC arm of GlaxoSmithKline.